RNS Number : 2168K
Genus PLC
23 August 2023

For Immediate Release

23 August 2023

Genus plc

Non-Executive Director Retirement

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director.

Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele.

Commenting on the retirement, Iain Ferguson, Chairman of Genus, said:

"On behalf of the Board I want to acknowledge Lykele's significant contributions to the Board's deliberations, bringing to the fore his experience and knowledge as a leader in growing agricultural businesses across global markets. We thank him for his contributions, we will miss his keen insight and business acumen during our Board discussions and wish him well for the future."

For further information please contact:

Genus:

Iain Ferguson, Chairman Tel: +44 (0)1256 345970

Jorgen Kokke, Chief Executive

Buchanan:

Charles Ryland /Chris Lane/ Verity Parker Tel: +44 (0)207 466 5000

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus' worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGIGDIBDDDGXX